The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwAL 2018 | We know that MRD is relevant, what next?
It is now widely agreed that minimal residual disease (MRD) is a clinically relevant measure, so how can we now move forward to achieve the widespread utilization of MRD measurement in a meaningful way? This question is explored here, in an interesting discussion with Bijal Shah, MD, of the H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL. Dr Shah raises the topic of what we should now define as complete and partial response rates, and whether we should still be using these terms. He also discusses the subjects of what weight should be given to different mutations, standardization, therapy guidance and impact on transplant. This video was recorded at the 1st International Workshop on Acute Leukemias (iwAL), held in St. Pete Beach, FL.
